The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Obesity and diabetes
Abstract
Obesity, which has currently reached pandemic dimensions, is usually accompanied by diabetes mellitus type 2 (T2DM). These two conditions share common pathophysiological mechanisms. Adipose tissue secretes cytokines which are involved in inflammation and various endocrine functions. As for T2DM, it is characterized also by inflammation, mitochondrial dysfunction, and hyperinsulinemia. These conditions occur also in other diseases related to obesity and T2DM, like cardiovascular disease (CVD) and nonalcoholic fatty liver disease (NAFLD). Thus, management of obesity-related complications with lifestyle modification, anti-obesity drugs, and bariatric surgery, all contribute to improvement in any of these conditions. This review provides an overview of the literature addressing the association between obesity and T2DM, briefly discussing the pathophysiological mechanisms linking these conditions and outlining the management approach at the overlap of obesity and T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Inflammation, stress, and diabetes
Wellen, K. E., & Hotamisligil, G. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25102 · Cited by 4,143
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., Wang, S., Fortier, M., Greenberg, A. S., & Obin, M. S. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500294-jlr200 · Cited by 2,529
Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 Diabetes
Petersen, K. F., Dufour, S., Befroy, D., Garcia, R., & Shulman, G. I. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031314 · Cited by 2,193
Research works printed but not linked: 94
- Boutari, 2018, Inflammation: A key player linking obesity with malignancies, Metabolism, 81, A3, 10.1016/j.metabol.2017.12.015 · DOI
- Wei, 2022, Effects of female obesity on conception, pregnancy and the health of offspring, Front Endocrinol (Lausanne), 13
- Polyzos, 2019, Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics, Metabolism, 92, 82, 10.1016/j.metabol.2018.11.014 · DOI · Paper page
- Polyzos, 2019, Obesity: seize the day, fight the fat, Metabolism, 92, 1, 10.1016/j.metabol.2018.12.011 · DOI
- Boutari, 2018, Association of adipokines with development and progression of nonalcoholic fatty liver disease, Endocrinol Metab, 33, 10.3803/EnM.2018.33.1.33 · DOI · Paper page
- Avgerinos, 2019, Obesity and cancer risk: Emerging biological mechanisms and perspectives, Metabolism, 92, 121, 10.1016/j.metabol.2018.11.001 · DOI · Paper page
- Gasbarrino, 2023, Relationship between circulating adipokines and cholesterol efflux in subjects with severe carotid atherosclerosis, Metabolism, 140
- Sahin-Efe, 2018, Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: A cross sectional and a prospective case-control study nested in the Normative Aging Study, Metabolism, 79, 24, 10.1016/j.metabol.2017.10.011 · DOI
- Perakakis, 2021, Leptin in leanness and obesity: JACC state-of-the-art review, J Am Coll Cardiol, 77, 745, 10.1016/j.jacc.2020.11.069 · DOI · Paper page
- Mantzoros, 1999, The role of leptin in human obesity and disease: A review of current evidence, Ann Intern Med, 130, 671, 10.7326/0003-4819-130-8-199904200-00014 · DOI · Paper page
- Jung C, Kim B, Mok J, … SK-J of diabetes, 2014 undefined. Association between serum adipocytokine levels and microangiopathies in patients with type 2 diabetes mellitus. Wiley Online Libr 2014;5:333–9. doi:10.1111/jdi.12144. · DOI
- Su, 2020, Emerging functions of adipokines in linking the development of obesity and cardiovascular diseases, Mol Biol Rep, 47, 7991, 10.1007/s11033-020-05732-9 · DOI
- Yadav, 2011, Correlation of adiponectin and leptin with insulin resistance: A pilot study in healthy North Indian population, Indian J Clin Biochem, 26, 193, 10.1007/s12291-011-0119-1 · DOI
- Muskiet, 2022, Obesity and leptin resistance in the regulation of the type I interferon early response and the increased risk for severe COVID-19, Nutrients, 14
- Degawa-Yamauchi, 2003, Serum resistin (FIZZ3) protein is increased in obese humans, J Clin Endocrinol Metab, 88, 5452, 10.1210/jc.2002-021808 · DOI · Paper page
- Yannakoulia, 2003, Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans, J Clin Endocrinol Metab, 88, 1730, 10.1210/jc.2002-021604 · DOI · Paper page
- Su, 2019, Relation of circulating resistin to insulin resistance in type 2 diabetes and obesity: A systematic review and meta-analysis, Front Physiol, 10
- Yang, 2023, Resistin impairs mitochondrial homeostasis via cyclase-associated protein 1-mediated fission, leading to obesity-induced metabolic diseases, Metabolism, 138
- Kawanami, 2004, Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine–endothelial cell interactions, Biochem Biophys Res Commun, 314, 415, 10.1016/j.bbrc.2003.12.104 · DOI · Paper page
- Rolph, 2002, Production of the long pentraxin PTX3 in advanced atherosclerotic plaques, Arterioscler Thromb Vasc Biol, 22
- Sethi JK, Hotamisligil GS. Metabolic Messengers: tumour necrosis factor n.d. doi:10.1038/s42255-021-00470-z. · DOI · Paper page
- Dahl, 2007, Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization, Circulation, 115, 972, 10.1161/CIRCULATIONAHA.106.665893 · DOI · Paper page
- Takumansang R, … SW-P, 2013 undefined. Interleukin-6 and insulin resistance in obese adolescents. PaediatricaindonesianaOrg 2013;53. · doi:10.14238/pi53.5.2013.06
- Vityala, 2022, Evaluation of metabolic syndrome, insulin secretion and insulin resistance in adolescents with overweight and obesity, Metab - Clin Exp, 128, 10.1016/j.metabol.2021.155011 · DOI
- Cao, 2022, Increased plasma fatty acid clearance, not fatty acid concentration, is associated with muscle insulin resistance in people with obesity, Metabolism, 132
- Ye, 2011, Regulation of stem cell differentiation in adipose tissue by chronic inflammation, Clin Exp Pharmacol Physiol, 38, 872, 10.1111/j.1440-1681.2011.05596.x · DOI
- Endocrine JY-, Disorders-Drug M& I, 2007 undefined. Role of insulin in the pathogenesis of free fatty acid-induced insulin resistance in skeletal muscle. IngentaconnectCom 2007. doi:10.2174/187153007780059423. · DOI
- Ye, 2013, Inflammation during obesity is not all bad: evidence from animal and human studies, Am J Physiol - Endocrinol Metab, 304, E466, 10.1152/ajpendo.00266.2012 · DOI · Paper page
- Weisberg S, McCann D, … MD-TJ of, 2003 undefined. Obesity is associated with macrophage accumulation in adipose tissue. Am Soc Clin Investig n.d. · DOI · Paper page
- Yao, 2022, Mitochondrial dysfunction in diabetic tubulopathy, Metab - Clin Exp, 131
- Wu Z, Puigserver P, Andersson U, Cell CZ-, 1999 undefined. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Elsevier n.d. · DOI · Paper page
- St-Pierre, 2003, Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells, J Biol Chem, 278, 26597, 10.1074/jbc.M301850200 · DOI · Paper page
- Norton, 2022, Insulin: The master regulator of glucose metabolism, Metab - Clin Exp, 129
- Gray S, Donald C, Jetha A, Endocrinology SC-, 2010 undefined. Hyperinsulinemia precedes insulin resistance in mice lacking pancreatic β-cell leptin signaling. AcademicOupCom n.d. · DOI
- Grespan, 2021, Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes, Metabolism, 114
- Angelidi, 2021, Novel non-invasive approaches to the treatment of obesity: From pharmacotherapy to gene therapy, Endocr Rev
- Ambati, 2011, GIP-dependent expression of hypothalamic genes, Physiol Res, 60, 941, 10.33549/physiolres.932151 · DOI
- Lakka, 2001, Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men, Atherosclerosis, 154, 497, 10.1016/S0021-9150(00)00514-1 · DOI · Paper page
- Liu, 2021, The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis, Metab - Clin Exp, 120
- Stevens, 2002, Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study, Am J Epidemiol, 156, 832, 10.1093/aje/kwf114 · DOI · Paper page
- Pontiroli, 2004, Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans, Eur J Endocrinol, 150, 195, 10.1530/eje.0.1500195 · DOI
- Kwiterovich, 2002, Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity, Am J Cardiol, 90, 30, 10.1016/S0002-9149(02)02749-2 · DOI · Paper page
- Howard, 2000, LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study, Arterioscler Thromb Vasc Biol, 20, 830, 10.1161/01.ATV.20.3.830 · DOI · Paper page
- Frénais, 2001, In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus, J Clin Endocrinol Metab, 86, 1962
- Smith, 2006, Free fatty acids and atherosclerosis—Guilty or innocent?, J Clin Endocrinol Metab, 91, 2506, 10.1210/jc.2006-1018 · DOI
- Pilz, 2006, Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease, J Clin Endocrinol Metab, 91, 2542, 10.1210/jc.2006-0195 · DOI · Paper page
- Rexrode, 1998, Abdominal adiposity and coronary heart disease in women, JAMA, 280, 1843, 10.1001/jama.280.21.1843 · DOI · Paper page
- McGavock, 2006, Adiposity of the heart, revisited, Ann Intern Med, 144, 517, 10.7326/0003-4819-144-7-200604040-00011 · DOI · Paper page
- Szczepaniak, 2003, Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging, Magn Reson Med, 49, 417, 10.1002/mrm.10372 · DOI · Paper page
- Verlohren S, Dubrovska G, Tsang SY, Essin K, Luft FC, Huang Y, et al. Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertens (Dallas, Tex 1979) 2004;44:271–6. doi:10.1161/01.HYP.0000140058.28994.EC. · DOI · Paper page
- Konstantinides, 2001, Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity, J Clin Invest, 108, 1533, 10.1172/JCI13143 · DOI · Paper page
- Singhal, 2002, Influence of Leptin on Arterial Distensibility, Circulation, 106, 1919, 10.1161/01.CIR.0000033219.24717.52 · DOI · Paper page
- Alessi, 2003, Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation, Arterioscler Thromb Vasc Biol, 23, 1262, 10.1161/01.ATV.0000077401.36885.BB · DOI · Paper page
- haematology CE-B journal of, 2005 undefined. The interactions between inflammation and coagulation. Wiley Online Libr 2005;131:417–30. doi:10.1111/j.1365-2141.2005.05753.x. · DOI · Paper page
- Boutari, 2021, Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward, Metab - Clin Exp, 122
- Meritsi, 2022, Factors associated with hepatic steatosis in adult Greek subjects with type 2 diabetes mellitus, Metabolism, 128, 10.1016/j.metabol.2021.154968 · doi:10.1016/j.metabol.2021.154968
- Chung, 2021, Nonalcoholic fatty liver disease increases the risk of diabetes in young adults: A nationwide population-based study in Korea, Metabolism, 123
- Saponaro C, Gaggini M, Carli F, Gastaldelli A. The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis 2015. doi:10.3390/nu7115475. · DOI · Paper page
- endocrinology HY-J-T lancet D&, 2014 undefined. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Elsevier n.d.
- Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013 106 2013;10:330–44. doi:10.1038/nrgastro.2013.41. · DOI · Paper page
- Trayhurn, 2013, Hypoxia and adipose tissue function and dysfunction in obesity, Physiol Rev, 93, 1, 10.1152/physrev.00017.2012 · DOI · Paper page
- Weisberg, 2003, Obesity is associated with macrophage accumulation in adipose tissue, J Clin Invest, 112, 1796, 10.1172/JCI200319246 · DOI · Paper page
- Turer, 2012, Adiponectin: Mechanistic insights and clinical implications, Diabetologia, 55, 2319, 10.1007/s00125-012-2598-x · DOI · Paper page
- Turer, 2012, Adiponectin as an independent predictor of the presence and degree of hepatic steatosis in the Dallas Heart Study, J Clin Endocrinol Metab, 97
- Machado M V, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease CONCISE REVIEW 2012;11:440–9. · DOI
- Elsayed, 2023, 14. Children and adolescents: Standards of care in diabetes—2023, Diabetes Care, 46, S230, 10.2337/dc23-S014 · DOI · Paper page
- Ballesteros-Pomar, 2022, Bioelectrical impedance analysis as an alternative to dual-energy x-ray absorptiometry in the assessment of fat mass and appendicular lean mass in patients with obesity, Nutrition, 93, 10.1016/j.nut.2021.111442 · DOI
- Burhans, 2018, Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus, Compr Physiol, 9, 1, 10.1002/j.2040-4603.2019.tb00055.x · doi:10.1002/j.2040-4603.2019.tb00055.x · Paper page
- Nadolsky, 2023, American Association of Clinical Endocrinology Consensus Statement: Addressing stigma and bias in the diagnosis and management of patients with obesity/adiposity-based chronic disease and assessing bias and stigmatization as determinants of disease severi, Endocr Pract, 10.1016/j.eprac.2023.03.272 · DOI · Paper page
- Lemos, 2017, Current body composition measurement techniques, Curr Opin Endocrinol Diabetes Obes, 24, 310, 10.1097/MED.0000000000000360 · DOI · Paper page
- Jensen, 2014, 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society, J Am Coll Cardiol, 63, 2985, 10.1016/j.jacc.2013.11.004 · DOI · Paper page
- Nachón, 2022, Epidemiological study on short and long-term weight loss with improvement of metabolic control in obese diabetic patients with a standardized multidisciplinary weight loss program (DIAMEX Study), Metabolism, 128, 10.1016/j.metabol.2021.155080 · doi:10.1016/j.metabol.2021.155080
- Salvia, 2017, The look AHEAD trial: Translating lessons learned into clinical practice and further study, Diabetes Spectr, 30, 166, 10.2337/ds17-0016 · DOI
- Gregg, 2012, Association of an intensive lifestyle intervention with remission of type 2 diabetes, JAMA, 308, 2489, 10.1001/jama.2012.67929 · DOI · Paper page
- Singh, 2019, Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials, BMJ Open, 9, e029966, 10.1136/bmjopen-2019-029966 · DOI
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes | NEJM n.d. https://www.nejm.org/doi/10.1056/NEJMoa1212914?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub 0www.ncbi.nlm.nih.gov. · DOI · Paper page
- Wexler, 2022, Results of a 2-year lifestyle intervention for type 2 diabetes: the Reach Ahead for Lifestyle and Health-Diabetes randomized controlled trial, Obesity, 30, 1938, 10.1002/oby.23508 · DOI
- Eight-Year Weight Losses with an Intensive Lifestyle Intervention: The Look AHEAD Study. Obesity (Silver Spring) 2014;22:5–13. doi:10.1002/oby.20662. · DOI · Paper page
- Veelen, 2023, Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial, Metabolism, 140, 10.1016/j.metabol.2022.155396 · DOI
- DeMarsilis, 2022, Pharmacotherapy of type 2 diabetes: An update and future directions, Metabolism, 137, 10.1016/j.metabol.2022.155332 · DOI
- Polyzos, 2021, Diabetes mellitus: 100 years since the discovery of insulin, Metabolism, 118
- Billes, 2014, Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss, Pharmacol Res, 84, 1, 10.1016/j.phrs.2014.04.004 · DOI · Paper page
- Apovian, 2013, A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II), Obesity (Silver Spring), 21, 935, 10.1002/oby.20309 · DOI · Paper page
- Hollander, 2013, Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients, Am Diabetes Assoc
- Watkins, 2023, Glucagon-like peptide-1 secretion in people with versus without type 2 diabetes: a systematic review and meta-analysis of cross-sectional studies, Metabolism, 140, 10.1016/j.metabol.2022.155375 · DOI
- le Roux, 2017, 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial, Lancet, 389, 1399, 10.1016/S0140-6736(17)30069-7 · DOI · Paper page
- Blonde, 2009, The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies, Diabetes Obes Metab, 11, 26, 10.1111/j.1463-1326.2009.01075.x · DOI · Paper page
- Daousi, 2009, Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes, Clin Endocrinol (Oxf), 71, 195, 10.1111/j.1365-2265.2008.03451.x · DOI
- Fukuda, 2021, The role of GIP receptor in the CNS for the pathogenesis of obesity, Diabetes, 70, 1929, 10.2337/dbi21-0001 · DOI
- Healthcare, 2023, AZ to terminate once-daily cotadutide program to focus on weekly GLP-1RA co-agonist, Pharm Technol
- Greenway, 2019, A randomized, double-blind, placebo-controlled study of gelesis100: A novel nonsystemic oral hydrogel for weight loss, Obesity, 27, 205, 10.1002/oby.22347 · DOI · Paper page
- Rubino, 2017, Metabolic surgery in the treatment algorithm for type 2 diabetes: a Joint Statement by International Diabetes Organizations, Obes Surg, 27, 2, 10.1007/s11695-016-2457-9 · DOI · Paper page
- Thorell, 2012, Treatment of diabetes prior to and after bariatric surgery, J Diabetes Sci Technol, 6, 1226, 10.1177/193229681200600528 · DOI
- Stenberg, 2022, Guidelines for perioperative care in bariatric surgery: Enhanced recovery after surgery (ERAS) society recommendations: A 2021 update, World J Surg, 46, 729, 10.1007/s00268-021-06394-9 · DOI · Paper page
Cited by
Liu, L., Shi, H., Xie, M., Sun, Y., & Nahata, M. C. (2025) · Pharmaceuticals · doi:10.3390/ph18050668 · Cited by 19
Metadata
- Authors
- Boutari, C., DeMarsilis, A., & Mantzoros, C. S.
- Venue
- Diabetes Research and Clinical Practice
- Publisher
- Elsevier BV
- Published
- 2023-08
- Volume
- 202
- Pages
- 110773
- ISSN
- 0168-8227 (ISSN-L)
- OpenAlex
- W4381893510
- Cited by
- 161
- References
- 78
- FWCI
- 26.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Obesity and diabetes. https://app.cochat.ai/papers/10.1016/j.diabres.2023.110773
- The paper
- Boutari, C., DeMarsilis, A., & Mantzoros, C. S. (2023). Obesity and diabetes. Diabetes Research and Clinical Practice. https://doi.org/10.1016/j.diabres.2023.110773
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.